Register authorizing the use of liquid chromatography-tandem mass spectrometry (LC-MS-MS) and other technologies in federally regulated workplace drug testing (WPDT) programs. These rules are expected to become effective in May 2010. To support this change, it is essential to explicitly demonstrate that LC-MS-MS as a technology can produce results at least as valid as gas chromatography-mass spectrometry (GC-MS), the longaccepted standard in confirmatory analytical technologies for drugs of abuse and currently the only confirmatory method allowed for use in support of federally regulated WPDT programs. A series of manufactured control urine samples (n = 10 for each analyte) containing benzoylecgonine, morphine, codeine, and 6-acetylmorphine at concentrations ranging from 10% to 2000% of federal cutoffs were analyzed with replication by five federally regulated laboratories using GC-MS (five replicate analyses per lab) and at RTI International using LC-MS-MS (10 replicate analyses). Interference samples as described in the National Laboratory Certification Program 2009 Manual were also analyzed by both GC-MS and LC-MS-MS. In addition, matrix effects were assessed for LC-MS-MS, and both analytical technologies were used to analyze previously confirmed urine specimens of WPDT origin. Results indicated that LC-MS-MS analysis produced results at least as precise, accurate, and specific as GC-MS for the analytes investigated in this study. Matrix effects, while evident, could be controlled by the use of matrix-matched controls and calibrators with deuterated internal standards. LC-MS-MS data parameters, such as retention time and product ion ratios, were highly reproducible.
Introduction
On November 25, 2008, the U.S. Department of Health and Human Services (HHS) published a final notice in the Federal Register allowing the use of liquid chromatography-tandem mass spectrometry (LC-MS-MS) and other technologies in federally regulated workplace drug testing (WPDT) programs (1). This is anticipated to become effective in May 2010. To support this change, it is essential to explicitly demonstrate that LC-MS-MS as a technology can produce results at least as valid as gas chromatography-mass spectrometry (GC-MS). GC-MS has been the accepted standard in confirmatory analytical technologies for drugs of abuse in urine and is currently the only confirmatory method allowed for use in support of federally regulated WPDT programs. A very large body of literature is available with validation studies for GC-MS methods (2, 3) .
Numerous validation studies have been published utilizing LC-MS-MS methods for a wide variety of target analytes in urine, oral fluid, and blood (3) (4) (5) (6) (7) (8) (9) (10) (11) . Most of these studies provide data documenting accuracy, precision, linearity, and interferences (12, 13) . These criteria are required to demonstrate that a method is valid and capable of producing accurate, precise, and reliable results. Additional data are needed to support the minimal technical criteria that define acceptable instrument and batch performance for the application of LC-MS-MS in WPDT.
This study attempted to evaluate the detection of benzoylecgonine (BZE), morphine (MOR), codeine (COD), and 6-acetylmorphine (6-AM) in urine using LC-MS-MS. In a previous study, Fox and colleagues (11) discussed issues of identification of some opiates using LC-MS-MS. One goal of this study was to evaluate and compare the detection of MOR, 
Linearity, precision, and accuracy determination by LC-MS-MS and GC-MS analyses
The LPA sample series (Table I) was analyzed by five HHScertified drug testing laboratories using GC-MS and was also analyzed by RTI using LC-MS-MS. The samples, along with control materials derived from past NLCP PT materials, were shipped frozen overnight from RTI to the laboratories. These control materials provided known reference points to allow deviations from expected performance to be attributed to issues within the laboratory or to the manufactured sample materials. Each laboratory was provided with sufficient sample volume for all requested analyses and was compensated for their analyses.
The OPI and BZE series of manufactured samples were analyzed with each laboratory using its standard validated GC-MS methods. Each laboratory was instructed to extract one set of samples and to analyze each extract five times by GC-MS using five separate calibrations within a five-day period. Because the purpose of the study was to evaluate the differences in analytical method performance, this protocol limited the variation because of extraction procedures. RTI also extracted and analyzed the OPI and BZE series using LC-MS-MS for a total of 10 separate extractions and analyses for each series over a 5-day period (i.e., two extractions were conducted each day).
Interference samples
Opiates interference samples (Table II) also were shipped to the five separate reference laboratories for GC-MS analysis. Laboratories were instructed to analyze the materials once using their standard opiates extraction and GC-MS procedures. Five replicate LC-MS-MS analyses of these materials were performed at RTI.
Matrix effect samples
Matrix effect samples were analyzed only by LC-MS-MS at RTI. Matrix effects were evaluated using the methods described by Matuszewski and colleagues (17) . In brief, three sets of samples were created for each target analyte. Type A samples (neat in mobile phase) were made by preparing an amount of target analyte and internal standard in mobile phase equivalent as in sample types B and C. Type B samples (post-extraction spike) were made by fortifying the eluent from the solid-phase extraction of negative urine matrix with target analytes and internal standard. Type C samples (pre-extraction spike) were made by fortifying negative urine matrix with target analytes and internal standard prior to solid-phase extraction. Target analyte concentrations were prepared at cutoff concentrations for each drug: 2000 ng/mL MOR/COD, 150 ng/mL BZE, and 10 ng/mL 6-AM. For the purposes of this study, 10 lots of urine, each from a different donor, were collected and samples were analyzed once.
As described by Matuszewski and colleagues (17) , comparative calculations were used to evaluate the data: ME (%) = B/A × 100 RE (%) = C/B × 100 PE (%) = C/A × 100 where A, B, and C = the mean responses as represented by the area under the peaks for target and internal standard quantitative ions, ME = the matrix effect, RE = the recovery effect ("recovery of the extraction procedure"), and PE = the process effect ("process efficiency").
The mean responses for A, B, and C were determined across these 10 urine lots. Additionally, a comparison of the relative matrix effect was accomplished by comparing the percent coefficient of variation (%CV) in the response across the 10 matrix lots for sample types B and A. This provided a comparison of the variation due to analysis as represented by the %CV of sample type A (neat in mobile phase) with the variation due to matrix represented by the %CV of sample type B (post-extraction spike).
Previously confirmed specimens
Previously confirmed urine specimens were obtained from Laboratory Corporation of America Holdings (LabCorp, Research Triangle Park, NC). All specimens had been slated for destruction, and all identifiers were removed prior to shipment to RTI. Urine specimens from LabCorp were previously confirmed positive for BZE, COD, MOR, and/or 6-AM. LabCorp reanalyzed the specimens using GC-MS concurrently with RTI's LC-MS-MS analysis. Sixty BZE and 46 opiate samples previously confirmed positive were utilized.
LC-MS-MS analysis conducted at RTI
BZE extraction. Fifty microliters of methanolic deuterated internal standard (ISTD) (final concentration: 500 ng/mL BZE-d 3 ) was added to a 1-mL sample of urine, and 3 mL of sodium phosphate buffer (100 mM, pH 6) was added to the sample. The sample was vortex mixed and centrifuged at 3000 rpm for 5 min.
The sample was transferred to a solid-phase extraction column (SPEware Polychrom™ Clin II, 35 mg) and allowed to flow by gravity before the column was rinsed with 1 mL of deionized (DI) water followed with 1 mL of 100 mM hydrochloric acid (HCl) and then dried under nitrogen (N 2 ) at 25 psi for 2 min. The column was rinsed a second time with 1 mL each of methanol followed with ethyl acetate and then dried for 2 min at 25 psi N 2 . The drugs were eluted by gravity with 2 mL of dichloromethane/isopropyl alcohol/ammonium hydroxide (80:14:2). The eluent was evaporated under a stream of N 2 to dryness at 40°C and reconstituted in 0.1 mL of 5 mM ammonium formate/acetonitrile (95:5) with 0.1% formic acid.
Opiate extraction. For LPA samples in which MOR was present in non-conjugated form, 30 µL of methanolic deuterated internal standard (final concentrations: 3000 ng/mL codeine-d 3 and morphine-d 3 and 30 ng/mL 6-AM-d 3 ) was added to a 1-mL sample of urine. Two milliliters of sodium acetate buffer (100 mM, pH 4.5) and 0.5 mL of 10% hydroxylamine hydrochloride were added to the sample. The sample was vortex mixed, centrifuged at 3000 rpm for 5 min, and heated in a water bath at 60°C for 1 h.
For archived samples in which the LC-MS-MS analysis was for total MOR, the following procedure was used: 30 µL of methanolic deuterated internal standard was added to a 1-mL urine sample. Half a milliliter of concentrated HCl and 0.5 mL of 10% hydroxylamine were added to the sample. The sample was autoclaved at 121°C for 20 min (total cycle time of 50 min). Once the sample cooled, 0.5 mL of 45% potassium hydroxide (KOH) was added and the sample mixed. Then 0.5 mL of saturated sodium bicarbonate (NaHCO 3 ) was added, and the sample was vortex mixed. Previously used PT samples were included in these batches as controls. These samples contained morphine glucuronide to control for the hydrolysis of morphine in these samples.
After either pretreatment step, the sample was poured into solid-phase extraction columns (SPEware Polychrom Clin II, 35 mg) that had been preconditioned with 2 mL each of methanol, DI water, and 0.1 M acetic acid. The column was washed with 2 mL each of acetic acid, DI water, hexane, and methanol. After the addition of the hexane and methanol, the column was dried at 25 psi for 5 min. The drugs were eluted with 2 mL of dichloromethane/isopropyl alcohol/ammonium hydroxide (80:14:2) by gravity and evaporated under N 2 to dryness at 40°C and reconstituted in 0.1 mL of 5 mM ammonium formate/acetonitrile (ACN) (95:5) with 0.1% formic acid.
LC-MS-MS method.
The LC-MS-MS equipment consisted of an Agilent 1200 series LC coupled to an Agilent 6410 triple-quadrupole MS with an electrospray source (Santa Clara, CA). Table III lists the LC method conditions used. The mobile phase components were (A) 5 mM formate (with 0.1% formic acid) and (B) acetonitrile (with 0.1% formic acid). All analyses were conducted in MRM mode using the MS-MS conditions and ions listed in Table IV . Collision energies and capillary voltages were optimized for each ion.
Calibration. The calibration method used for the quantification of each drug analyte is given in Table V . Calibration and data reduction were accomplished using Mass Hunter software (San Jose, CA). For all compounds, LC-MS-MS analysis was conducted using both a five-point calibration and a one-point calibration with a single calibrator at the federally mandated cutoff concentration (1). The calibration type (i.e., linear or quadratic) for a five-point calibration was optimized for each compound and was used throughout the study. For the acceptance of data analyzed, control quantitation for batches had to be within 20% of the target concentration for the control. At least 10 data points across the peak were needed. Even for the MOR/COD/6-AM analyses, there were typically more than 20 data points across peaks. The ratio of the product ions had to be within 20% of the average of the calibrator ratios, and the retention time had to be within 2% of the average of the calibrators. Calibrators were back-calculated against the model curve, and the back calculated value had to be within 20% of their theoretical concentration. Statistical analysis. Statistical tests conducted using Microsoft Excel 2003 (Seattle, WA) included linear regression analyses with subsequent analysis of variance (ANOVA) of the regression fit, calculation of average, standard deviation, and %CV. Student t-tests were used for the comparison of analyses of the previously confirmed specimens. For these tests, significance was assigned at the p < 0.05 level.
For the comparison of GC-MS and LC-MS-MS analyses of the LPA samples, a two-way imbalanced ANOVA was conducted (SAS PROC GLM using SAS, Raleigh, NC). If the crossed term of analytical method and concentration was significant, the two methods were compared after adjusting for the effect of the expected concentration. This allowed for the determination of significant differences between the two analytical methods at each concentration in the analyzed series. Again, significance was assigned at the p < 0.05 level.
Results and Discussion

Materials analyzed by both GC-MS and LC-MS-MS
The precision and accuracy of results from the five HHScertified laboratories conducting GC-MS analyses are presented in Table VI , and the analogous LC-MS-MS results are presented in Table VII .
For GC-MS results, within-laboratory precision represented by %CV was very tight (< 3% CV). Between-laboratory %CV was less than 10% for all compounds except 6-AM, which demonstrated greater between-laboratory variability with a 13.15% CV. The number of samples (n in Table VI) used for this analysis varied for each compound because samples not meeting acceptance criteria for GC-MS (e.g., ion ratios outside the acceptable range) were excluded. The excluded samples (i.e., 6 for BZE, 13 for MOR, 13 for COD, and 21 for 6-AM) were at either the lowest concentration or the highest concentration of the series (i.e., samples at 10% of cutoff or 2000% of cutoff). The values for controls were not included in this analysis.
In Table VI , accuracy for GC-MS analyses was assessed by determining % accuracy and regression analysis comparing target concentration with measured concentration. First, % accuracy (measured concentration/target concentration × 100) was determined. This allowed the calculation of the average % accuracy for each drug analyte and the associated %CV. All drugs were 95.2-101.9% accurate for GC-MS with accuracy %CVs less than 6.5%. The second means of assessing accuracy was a regression analysis comparing target concentration with measured concentration. If results were completely accurate and precise over the entire range tested, the regression results would theoretically be an r 2 = 1.000, a slope of 1.000, and an intercept of 0.000. A theoretically perfect analytical precision would yield an ANOVA analysis indicating that a model-fit with a slope significantly different than 0.000 and an intercept not significantly different than 0.000. As indicated in Table VI , all GC-MS results were very close to ideal, indicating the results were highly precise and accurate. Because the highest concentration point (i.e., 40,000 ng/mL) for MOR and COD was above some of the laboratories' upper limits of linearity (ULOL), this point was not used in the regression and accuracy analyses for GC-MS results.
Qualitatively, LC-MS-MS results demonstrated good chromatographic performance, exhibiting symmetrical peaks and at least 90% resolution with adjacent peaks. An example of typical chromatography observed in the LC-MS-MS is presented in Figure 1 .
The LC-MS-MS sample results as presented in Table VII were quantitated using both a five-point calibration, as described in the methods for each drug, and a one-point calibration using a cutoff calibrator (i.e., the calibration method most commonly used in workplace testing). Similar to GC-MS analysis, calculations for precision and accuracy for LC-MS-MS results are presented in Table VII. For most analytes, the average %CV was highly comparable for five-point and one-point calibrations for LC-MS-MS results. MOR results were notably less precise when the quantitation was calculated by a one-point calibration at 2000 ng/mL because of results from the highest concentration points (20,000 and 40,000 ng/mL). The average overall %CV was higher for all analytes using the one-point calibration for LC-MS-MS analyses than the average within-laboratory %CV for GC-MS results. This is due to the exclusion of points above the reported ULOL and limits of detec- 
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tion (LOD) for GC-MS analyses but not for LC-MS-MS.
Accuracy was again assessed by calculating average accuracy and performing the same regression analysis as for GC-MS results. LC-MS-MS analyses were comparably accurate, ranging between 99.8% and 102.0% accurate when using a five-point calibration and 97.0% and 105.9% accurate when using a onepoint calibration.
For the purposes of this study, the LC-MS-MS results obtained with a five-point calibration and best fit to a quadratic or linear equation were used for comparison with GC-MS results. This comparison produced very good calibration results, as indicated by control materials and back-calculating calibrators against the model curve.
When GC-MS and LC-MS-MS results at each concentration were compared using a two-way ANOVA, no significant difference (p < 0.05) was observed at any concentration for BZE and 6-AM. For MOR, a significant difference was observed for the 40,000 ng/mL concentration (p = 0.019, LC-MS-MS mean = 40,200 ng/mL, GC-MS mean = 36,800 ng/mL, or a 9% difference). This concentration was above the limit of linearity reported by most of the laboratories for GC-MS analysis. For COD, significant differences were observed for all of the concentrations listed in Table VIII . Although statistically significant, the differences were small (< 10%) for all but the 40,000 ng/mL sample, which was above most laboratories' reported limit of linearity.
In the evaluation of performance testing samples in the NLCP, results are evaluated for error of quantitation deviating more than 20% or 50% from the target for any given sample (18) . Table IX summarizes the comparison of GC-MS and LC-MS-MS results evaluated with this 20% and 50% criteria. For concentrations between 40% and 1000% of the cutoff, neither GC-MS nor LC-MS-MS had any 50% errors, and there were only four 20% errors (by GC-MS) for low-concentration 6-AM. This indicated that LC-MS-MS is at least as capable as GC-MS at producing acceptable results as would be required on performance testing samples in the NLCP. Table X compares the results of the interference samples detailed in Table II when analyzed by both GC-MS and LC-MS-MS. These samples contained the interferants (NCOD, HYC, HYM, OXC, and OXM) at 5000 ng/mL in the presence of analytes of interest at 40% of cutoff concentrations and in the absence of the analytes of interest altogether. The mean quantitative result from GC-MS and LC-MS-MS analyses were compared using the Student t-test with significance assigned at p < 0.05. Only the 6-AM results from LC-MS-MS with OXC and OXM present were significantly different than the GC-MS result (p = 0.002). Figure 2 presents typical chromatography observed for the LC-MS-MS analysis of samples containing structural analogue compounds as potential interferants in the presence of target analytes at 40% of cutoff concentrations. There was a slight shoulder on one 6-AM peak in the sample containing NCOD; however, this met chromatography acceptance criteria (i.e., 90% resolution). No MOR, COD, or 6-AM was detected in the interference samples without the addition of target compound and high concentrations of structural analogue compounds analyzed by GC-MS. For LC-MS-MS, 72 ng/mL COD was quantitated in samples containing 5000 ng/mL NCOD and no COD. It was unclear whether COD was present as a contaminant in the NCOD stock material used to manufacture the samples, or if a slight carryover occurred during the manufacture of the samples. The presence of this low concentration of COD did not appear to affect the quantitation of COD in the samples containing COD at 40% of the cutoff concentration. As can be seen in Table X , the average COD result was within 10% of the target, and there was no significant difference between the GC-MS and LC-MS-MS results by Student t-test. The only compound with significantly different GC-MS and LC-MS-MS results was 6-AM with OXC/OXM present with an average GC-MS result of 4.5 ng/mL and an average LC-MS-MS result of 3.6 ng/mL. Although statistically significant, this difference was small and not indicative of interference due to the presence of the structural analogues. GC-MS and LC-MS-MS results were both unaffected by the presence of structural analogue compounds that might possibly interfere with analyses. Figure 3 presents a comparison of the average accuracy of GC-MS and LC-MS-MS results across the concentration range tested for each target compound. The error bars represent one standard deviation (SD) for each average. From this, it is apparent that the average accuracies across the concentration range are very similar for GC-MS and LC-MS-MS. The notable exceptions are for 6-AM GC-MS results at the 10% of cutoff concentration and for MOR and COD results at 2000% of the cutoff concentration. The 10% of cutoff 6-AM and the 2000% of cutoff MOR and COD concentrations were outside the limits of quantitation for GC-MS analyses for many laboratories; thus, low accuracy at these concentrations would be expected for the GC-MS analysis.
Table IX. Summary of the Number of Samples by Each Method (GC-MS and LC-MS-MS
Table X. Summary of Comparison of Interference Samples Analyzed by GC-MS and LC-MS-MS* GC-MS Analysis LC-MS-MS Analysis
Evaluation of LC-MS-MS data components and matrix effects
For LC-MS-MS results, Table XI summa- Example chromatography for COD, MOR, and 6-AM with the presence of 5000 ng/mL of each structural analogue to evaluate as an interfering compound. The top row of chromatograms for each target is the target compound; the lower row is the ISTD. All compounds were unaffected by the presence of high concentrations of the interfering compounds. The ISTD for 6-AM had a close shouldering peak that was resolved (as determined by the valley between the peaks being 10% of the 6-AM-d 3 peak).
rizes the averages and distributions of other qualifier data for the results, such as retention time (RT), ion ratios, and ISTD responses. The distributions of RTs for both target analyte and ISTD were very tight with %CVs less than 2% for all compounds. The ratio of quantitation product ion to qualifier product ion for both target compounds and ISTD demonstrated little variation with %CVs less than 5% for all target analytes except 6-AM. As would be expected, internal standard responses were more variable. The NLCP requires that internal standard ion response for the quantifying ion of a specimen be within 0.5 and 2 times of that obtained with the calibrator, the average of calibrator and controls, or the average of all calibrators, controls, and specimens in the analytical batch (18) . Although the %CVs are large, few samples fell outside of current NLCP criteria. Only three BZE and two COD samples (3% and 2% of samples, respectively) exhibited low internal standard response outside the acceptable range. For MOR, the 40,000 ng/mL sample consistently exhibited low internal standard responses (8 of the 10 replicate analyses of this concentration), and this is consistent with ion suppression of the internal standard by the elevated concentration of MOR.
Matrix effect was assessed only for LC-MS-MS results. Table XII summarizes the results of the matrix effect analysis. For COD, MOR, and 6-AM, there was a slight ion enhancement indicated by the matrix effect % greater than 100. BZE did not exhibit a matrix effect (ME % = 100). The same calculations are presented for the internal standard. Although there was an apparent ion enhancement effect, there was no relative matrix effect indicated by the similar (if not lower) variability (%CV) in responses of target compounds spiked into 10 different lots of urine (sample type B) compared with the analysis of target compounds in mobile phase only (sample type A) or compared with the variability of target compounds spiked into a single lot of urine. Table XII also gives the variability in a single lot of urine matrix for all target analytes. There is not a relative matrix effect (% CV < 10%) in the comparison of the %CV for five separate cutoff calibrators extracted and analyzed over five days. This material was prepared for all analyses from the same lot of urine and provides an indication of the variability due to a single lot of matrix. This variability is comparable to the variability observed across 10 different lots of urine matrix.
Though the matrix effect was small, there was an apparent difference in the quantitative MOR, COD, and 6-AM results of samples spiked before and after extraction. This difference is of importance when comparing the quantitative results of each sample type (A, B, and C). Table VIII summarizes quantitative results for each matrix effect evaluation sample type. Note that quantitation was based on a calibration curve constructed in urine matrix prior to extraction.
As can be seen in Table XIII , there is a slight (~12%) but significant difference in the quantitative values calculated for MOR, COD, and 6-AM in sample type A (neat in mobile phase) from sample types B (post-extraction spike) and C (pre-extraction spike). There was no significant difference between B and C. The neat in mobile phase sample quantitations are slightly above the target concentration, and the matrix containing samples are slightly below the target concentration.
This result, coupled with the apparent slight difference in matrix effect for the target compounds and ISTD evident in Table  XII , highlights the importance of the use of matrix-matched calibrators and controls that are subjected to the same treatment as samples. As there was no apparent relative matrix effect or differing matrix effect between urine lots, the matrix effect observed could be controlled for by the use of matrix-matched controls and calibrators. Further work is needed to determine whether synthetic urine has a comparable matrix effect to human urine used in this study and would be appropriate to use in general. Validation of any method using a synthetic matrix should include evaluation of the potential matrix effect.
Previously confirmed specimens
A comparison of the results for the previously confirmed specimens presented in Table XIV summarizes the regression analysis for the results of GC-MS and LC-MS-MS analyses. Previously confirmed samples were compared by a paired t-test and regression analysis of both analytical technologies. ISTD responses from GC-MS analysis and LC-MS-MS analysis are presented for comparison. Also, average RT and average product ion ratios are presented for the LC-MS-MS data. The RT and ion ratios were very tightly distributed, and the variability of ISTD responses were lower than GC-MS ISTD responses for these archived samples. There was no significant difference (p < 0.05) between the GC-MS and LC-MS-MS analyses of BZE and 6-AM. There were significant (p < 0.05) differences between the LC-MS-MS analyses of MOR and COD. MOR results were on average 5% greater by LC-MS-MS analysis than by GC-MS; so although statistically significant, the difference was very small. The COD results were on average 32% greater by LC-MS-MS. Likely, the difference in COD values was due to differences in the hydrolysis of samples. For LC-MS-MS analysis, the acid hydrolysis was conducted at 120°C (high pressure) for 20 min; 
